Ats Corporation · TSX:ATS
Ats — Q1 F2022 Earnings Presentation
10 slides from Ats's earnings presentation, Aug 11, 2021
Slide 1: First Quarter F2022 Earnings Presentation
First Quarter F2022 Earnings Presentation August 11, 2021
Slide 2: Forward Looking Statements & Non-IFRS Measures
Forward Looking Statements & Non-IFRS Measures This presentation and the oral statements made during this call contain certain statements that constitute forward-looking information within the meaning of applicable securities laws ("forward-looking statements"). Such forward-looking statements invol
Slide 3: Quarterly Highlights
Quarterly Highlights ▪ Strong business performance shows ATS continues to execute well ▪ Record Order Bookings (up 96% y/y) & healthy Order Backlog provide good revenue visibility ▪ Revenues up 57% y/y (28% sequentially) driven by recent acquisitions and strong showing from Life Sciences, Transporta
Slide 4: Q1 F2022 Financial Results
Q1 F2022 Financial Results (C$ mm, except per share data) Q1 F2022 Q1 F2021 Y/Y Change ($) Y/Y Change (%) Revenues $510.6 $324.9 $185.7 57.2% Earnings from operations 52.0 21.1 30.9 146.4% Revenue Growth: Adjusted earnings from 65.4 29.7 35.7 120.2% Organic 28.0% operations1 EBITDA1 75.8 39.2 36.6 9
Slide 5: Order Bookings & Backlog
Order Bookings & Backlog Quarterly Order Bookings1,2 LTM Order Bookings1,2 $1,938 $1,626 $1,468 $1,452 $1,519 $637 $1,370 $435 $463 $403 $356 $325 Q4-F20 Q1-F21 Q2-F21 Q3-F21 Q4-F21 Q1-F22 Q4-F20 Q1-F21 Q2-F21 Q3-F21 Q4-F21 Q1-F22 Backlog1 ▪ Strong quarterly bookings aided by acquisitions and $1,248
Slide 6: Cash Flow Generation
Cash Flow Generation Free Cash Flow1,2 Cash Flow from Operations1,2 $47 $48 $41 $34 Q1-F21 Q1-F22 Q1-F21 Q1-F22 Net Debt to Adj. EBITDA1 ▪ Quarterly CFO benefited from higher profitability 1.6x 1.6x 1.7x partially offset by higher WC investment ▪ FCF generation of $34mm lower y/y due to higher 0.8x
Slide 7: Summary
Summary ▪ Record Order Bookings and healthy Order Backlog ▪ Continued focus on margin expansion and deployment of ABM ▪ Activity levels picking up in Transportation; More traditional, non-Covid-19 opportunities in Life Sciences funnel ▪ Integration of CFT acquisition (completed in late March 2021) p
Slide 8: Appendix: Measures
Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures Notice to reader: Non-IFRS measures and additional IFRS measures Throughout this presentation management uses certain non-IFRS measures to evaluate the performance of the Company. The terms “operating margin”, “EBITDA”, “adjusted net inc
Slide 9: Appendix: Measures
Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures (C$ mm) 2017 F2018 F2019 F2020 F2021 Q1 Q1 (C$) Q1 Q1 F2022 F2021 F2022 F2021 Adjusted EBITDA 111.7 133.3 161.9 195.1 200.7 77.9 39.2 Basic earnings per share 0.37 0.11 Restructuring charges 2.3 11.2 - 26.6 14.3 - - Acquisition-related t
Slide 10: Appendix: Measures
Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures (C$ mm) Q1 Q1 (C$ mm) F2017 F2018 F2019 F2020 F2021 YTD F2022 F2021 F2022 Adjusted earnings from 65.4 29.7 Cash and cash equivalents 286.7 330.2 224.5 358.6 187.5 216.4 operations Acquisition-related transaction 2.1 - Bank indebtedness (